Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
164
resultados
Última actualización
20/04/2026 [07:36:00]
Resumen de: WO2026076634A1
Provided are Aβ375 related oligomers/aggregates in human brains and anti-Aβ3175 related oligomers/aggregates antibodies thereof. In addition, the using of anti-Aβ3175 related oligomers/aggregates antibodies for the treatment of Alzheimer's disease (AD) is also provided.
Resumen de: WO2026076481A1
The present disclosure related generally to polynucleotide sequences encoding an antigen-binding construct capable of specifically binding to intracellular tau, and uses thereof, in particular for the treatment of tauopathies, including Alzheimer's Disease.
Resumen de: WO2026080717A1
Methods and compositions for treating or reducing the development of neurodegenerative diseases.
Resumen de: WO2026077485A1
The present invention relates to an application of a DFNA5/GSDME inhibitor in preparing a drug for treating Alzheimer's disease. Also provided is an application of a specific DFNA5 gene knockdown system in preparing a drug for treating Alzheimer's disease. The present invention demonstrates that in reactive astrocytes of patients with Alzheimer's disease, the mRNA expression level of GSDME is significantly high, and GSDME can be used as an effective target for Alzheimer's disease. Provided is an application of a reagent, which specifically inhibits GSDME gene expression in astrocytes, in preparing a drug for treating Alzheimer's disease, so as to develop a novel treatment drug for Alzheimer's disease. The present invention demonstrates that the reagent, which inhibits GSDME gene expression, can be used for preparing a drug for treating Alzheimer's disease. The present invention also provides a theoretical basis for clinical treatment of Alzheimer's disease.
Resumen de: WO2026077862A1
The application relates to fused pyrimidinone derivatives of the general formula (I) which act as agonists of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) useful for the treatment of Parkinson's disease, rheumatoid arthritis, Alzheimer's disease, amyotrophic lateral sclerosis, Nasu-Hakola disease, frontotemporal dementia, multiple sclerosis, prion disease, and stroke.
Resumen de: WO2026078185A1
The present invention relates to a composition comprising a c-AMP Response Element-Binding protein 3 (CREB3), in particular a variant of CREB3 protein, or a nucleic acid molecule encoding said CREB3 protein or said variant of CREB3 protein, for use as a medicament, in particular for treating or preventing diseases associated with a degeneration of motor neurons. The present invention further relates to CREB3 protein, in particular said variant of CREB3 protein, as a biomarker for the stratification or the prognosis of patients suffering, or susceptible of suffering, from a disease associated with a degeneration of motor neurons.
Resumen de: WO2026079761A1
The present invention relates to a composition for alleviating, preventing, or treating Alzheimer's disease, the composition comprising apigenin and oxyresveratrol. A composition according to the present invention is highly effective in reducing Alzheimer's disease pathology caused by β-amyloid, which is increased by aging and oxidative stress, and improving β-amyloid-induced memory loss and cognitive function.
Resumen de: WO2026080811A1
Provided are methods and compositions for treating Parkinson's disease (PD). The compositions inhibit the expression or activity of adenosylmethionine decarboxylase 1 (AMD1).
Resumen de: US20260103445A1
The present invention relates to compositions comprising an RXR agonist, an RAR agonist, or a dual RXR/RAR agonist. The present invention further relates to methods of using the agonist compositions for treating or preventing dementia and cancer. In some embodiments, the dementia comprises Alzheimer's disease. In some embodiments, the cancer comprises leukemia.
Resumen de: WO2026077861A1
The application relates to fused pyrimidinone derivatives of the general formula (I) which act as agonists of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) useful for the treatment of Parkinson's disease, rheumatoid arthritis, Alzheimer's disease, amyotrophic lateral sclerosis, Nasu-Hakola disease, frontotemporal dementia, multiple sclerosis, prion disease, and stroke.
Resumen de: AU2024354107A1
Provided are an siRNA inhibiting the expression of an amyloid precursor protein (APP) gene in a human cell, a polypeptide-oligonucleotide drug, and a use. The siRNA has good APP expression inhibitory activity, and a suitable modification is made to the siRNA to improve the silencing capability against a target and reduce off-target activity. The siRNA and a conjugate thereof are expected to be applied for clinically preventing and treating an APP target-related disease such as cerebral amyloid angiopathy (CAA), early-onset familial Alzheimer's disease (EOFAD), or Alzheimer's disease (AD).
Resumen de: US20260103474A1
The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormality associated with TDP-43 aggregates or a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Frontotemporal dementia (FTD) and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: WO2026077305A1
Provided are a method and a drug combination for preventing or treating neurodegenerative diseases, comprising a pharmaceutical composition and a combination drug product. The drug combination, the pharmaceutical composition, and the combination drug product can be used to treat and/or prevent neurodegenerative diseases in patients, preferably neurodegenerative diseases associated with α-synuclein aggregation, and more preferably Parkinson's disease.
Resumen de: WO2026077393A1
The present invention belongs to the field of biopharmaceuticals. Disclosed are a Muse cell-derived protein complex, a preparation method therefor, and use thereof. The composition of the protein complex is: a stem cell lysate of Muse cells after being cultured in a stress environment for a predetermined time, or a protein complex obtained by separating and purifying the stem cell lysate. The protein complex has a good cell damage repair effect, especially a strong ability to repair nerve cell damage, and is expected to be used for treating neurodegenerative diseases, cerebral stroke, cerebrovascular disease, arthritis, enteritis, recovery after trauma, autism, depression, and pulmonary fibrosis. In particular, the neurodegenerative diseases include, but are not limited to, Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and different types of spinocerebellar ataxia (SCA).
Resumen de: WO2026077192A1
Provided in the present invention are preparation and use of a novel MAO-B inhibitor containing a tetralin-1-amine structure, which belong to the field of medicines. The derivative is a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. The compound of the present invention can be used for inhibiting monoamine oxidase (MAO), especially selectively inhibiting MAO-B. The compound can be used for treating diseases such as Parkinson's disease, Alzheimer's disease, and emotional disorders, and exhibits good application prospects.
Resumen de: EP4725321A1
0001 The present invention provides a medical food composition comprising at least one probiotic and optionally one or more amino acids. The composition is useful in patients with Parkinson's disease to enhance the systemic stability and central bioavailability of levodopa (L-DOPA). It exerts effects by modulating gut microbiota, reinforcing intestinal barrier integrity, and reducing systemic inflammation and oxidative stress, thereby improving motor and non-motor symptoms and minimizing L-DOPA-induced long-term side effects such as dyskinesia.
Resumen de: EP4725322A1
The present invention relates to a probiotic cocktail medical food composition and its use in delaying the progression of Parkinson's disease. The composition comprises: (a) at least one probiotic with neuroprotective or metabolic regulatory functions; (b) a functional amino acid combination comprising four or more essential amino acids. The composition can be formulated as a medical food product for improving or alleviating pathological conditions associated with Parkinson's disease, including motor dysfunction, cognitive decline, inflammation, and mitochondrial impairment. It is suitable for daily nutritional supplementation and disease progression delay in patients with Parkinson's disease or individuals at high risk.
Resumen de: EP4725506A2
The present disclosure provides novel methods for treating or preventing amyotrophic lateral sclerosis (ALS), methods for delaying the onset of neurological symptoms associated with ALS, increasing survival in subjects afflicted with ALS, and attenuating the decline of muscle strength associated with ALS in a subject in need thereof. The present disclosure also provides methods for treating or preventing α-synucleinopathy or TDP-43 proteinopathy. The methods comprise administering to the subject an effective amount of a mitochondriatargeting peptidomimetic compound, such as (R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof.
Resumen de: EP4725499A1
The present invention is related to the biomedical and biopharmaceutical sectors. Specifically, it refers to a chimeric antigen comprising the combination of the amino and carboxyl terminal regions of the amyloid beta peptide (Aβ), the amino and carboxyl terminal regions of the tau protein and a T cell epitope. The pharmaceutical composition comprising this chimeric antigen and at least one pharmaceutically acceptable vaccine adjuvant increases the efficacy of immunotherapy for the prevention and treatment of Alzheimer's Disease (AD). The chimeric antigen exerts its action by stimulating a multitarget humoral response with high titers of anti-Aβ and anti-tau antibodies simultaneously. This favors the combined elimination of toxic species of both Aβ and tau from the brain, which prevents or significantly improves the clinical symptoms and neuropathology of AD.
Resumen de: EP4725497A1
The present invention relates to a pharmaceutical composition for use in preventing or treating periodontal disease, or atherosclerosis or Alzheimer's disease caused by periodontal disease, more particularly, a pharmaceutical composition comprising a peptide having the amino acid sequence of SEQ ID NO: 1 to prevent or treat the periodontal disease or the atherosclerosis or Alzheimer's disease caused by periodontal disease, so that it is effective in suppressing osteoclastogenesis, suppressing Porphyromonas gingivalis colony formation, and suppressing gingipain expression. Further, the pharmaceutical composition is safe to a living body and involves less side effects including abnormal response.
Resumen de: US20260098038A1
Provided are a compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, where the. The compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
Resumen de: US20260097130A1
The present invention provides a method of treating neurodegenerative diseases. The method comprises the step of administering to a subject in need thereof an effective amount of a polymer-flavonoid conjugate, or a nanocomplex having an outer shell comprising one or more polymer-flavonoid conjugates and optionally an inner shell comprising one or more flavonoid oligomer and a drug such as anti-CD3 or anti-CD33 encapsulated within the shells. The present method brings therapeutic effective materials through blood-brain barrier to treat neurodegenerative diseases. The present method is effective to treat neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Lewy body dementia and Huntington's disease.
Resumen de: WO2026074007A1
The present relates to novel nuclear receptor related 1 (Nurr1) modulators, preferably agonists, having a new carboxylic acid/carboxamide bioisosteric moiety Y and being optionally deuterated, pharmaceutical formulations comprising them, a process for their preparation and their use as medicament, alone or in combination with one or more additional agents, for treating of various diseases, wherein the modulation of Nurr1 is beneficial in such diseases (e.g. multiple sclerosis or Parkinson's disease).
Resumen de: US20260098030A1
0000 Described are 6-aryl isoindolin-1-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessivecompulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.
Nº publicación: US20260097054A1 09/04/2026
Solicitante:
NUTRITION21 LLC [US]
Resumen de: US20260097054A1
0000 The present disclosure relates to the use of inositol-stabilized arginine (“ASI”) for improving cognition. For example, in some implementations, methods include administering an amount of ASI effective to improve cognition in humans. Some embodiments include the use of ASI for improving mental focus and/or attention span. For example, in some implementations, methods include administering an amount of ASI effective to improve mental focus and/or attention span in humans. Some embodiments include the use of ASI for treating and/or preventing cognitive disorders. Cognitive disorders may include stroke, anoxic brain injury, traumatic brain injury, dementia, Alzheimer's disease, Parkinson's disease, MCI, and age-related memory loss, attention deficit hyperactivity disorder (“ADHD”), and other learning disabilities.
BOPI
Sede Electrónica
